Preabilitazione online per pazienti in attesa di trapianto di fegato (OPAL)
OPAL: preabilitazione online per i pazienti in attesa di trapianto di fegato: uno studio controllato randomizzato multicentrico per ridurre la fragilità fisica e migliorare i risultati di salute
Physical frailty is common in patients awaiting liver transplantation and has been associated with poor health outcomes. There is promising data from small studies showing that behavioural, nutrition, exercise therapy (prehabilitation) improves physical function in patients while they are waiting for a liver transplant.
The proposed trial will assess if a 12-week online prehabilitation program improves physical function in patients listed for liver transplantation. Over 4 years, 177 patients will be recruited from 6 transplant centres across Canada and will be randomized to receive either the online prehabilitation program or usual care.
The primary outcome of physical function will be evaluated using the FTSST at baseline and 12 weeks (or last timepoint before transplant) assessed virtually or in-person. Secondary outcomes include liver specific physical frailty, aerobic fitness, health-related quality of life (QoL), participant experience and acceptability. Exploratory outcomes include other virtual and in-person physical function measures, covert hepatic encephalopathy (CHE), sarcopenia, malnutrition, adherence, behaviour factors, clinical and post-transplant outcomes. Results will be compared between the intervention and usual care groups.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This multi-centre randomized controlled trial (RCT) will be completed across the six major LT programs in Canada: Vancouver, Edmonton, Calgary, Toronto, London, and Montreal.
Participants involved in this study will be LT transplant candidates with cirrhosis who are receiving care at one of the six participating LT programs.
Participants will be assessed for eligibility, provided informed signed consent, complete baseline testing and then be randomized to the prehabilitation arm or usual care. Participants will be randomized in a 2:1 ratio between groups.
Prehabilitation Arm:
The 12 week prehabilitation program includes exercise, nutrition and psychological components that is accessed through the online digital web platform.
- The nutrition program includes a nutritional assessment, provision of a daily protein intake target (1.2-1.5 g/kg/day), online group sessions, and follow ups. Participants will also be provided with a clinically tested whey protein powder supplement with dosage based on their malnutrition scoring done at baseline. Follow ups will also be provided based on malnutrition scoring done at baseline.
- The exercise program includes an exercise assessment, follow along exercise videos, and weekly virtual live exercise sessions. The exercise specialist will advise one of three levels of exercise programming for each participant. Participants will be advised to complete 3 exercise sessions weekly from a combination of virtual group sessions and follow along videos and to participate in planned aerobic activity as much as possible.
- The weekly acceptance and commitment therapy based educational videos focus on reducing stress and anxiety and improving motivation and adherence.
Control/Usual Care Arm:
This group will receive standard care for LT candidates with cirrhosis and will be provided with standard online exercise, nutrition, and behavioural resources. Control participants will not receive access to the online digital platform. A short questionnaire will be sent to control participants every 4 weeks to track changes in physical activity.
Post-Transplant follow-up In the subgroup of patients who undergo LT, the same in-person and virtual testing will be carried out at 12 weeks post-transplant (timing may vary due to site clinic flow)
Data Collection Plan
Sample size calculations are based on the primary outcome (the chair stand test: time to complete 5 sit-to-stands) using individual data from our local exercise study in cirrhosis (n=59), plus our sit-to-stand data from our study of 694 patients. After accounting for lack of trial completion, loss to follow up, the total sample size is 177, with 59 participants in the control and 118 in the intervention arm.
- Quantitative outcomes: Baseline and primary/secondary/exploratory outcome data will be collected with in-person and/or virtual visits at baseline, week 12 (end of trial) and 12 weeks post-transplant (in the subgroup of patients who undergo LT). Charts will be reviewed for information on death, hospitalization, ambulatory care visits, medications and transplantation for up to 2 years after randomization in all participants. Dietary intake data (24-hour recall) may be collected using third party software.
- Qualitative data: Interviews/Focus groups will be conducted at the end of the study in a virtual format. Participation in the interviews/focus groups will be optional.
Types of analyses
- Quantitative outcomes: Baseline demographic and clinical characteristics will be compared between groups to identify differences that may exist despite randomization. Continuous variables will be screened for assumptions of normality, and descriptive analyses will be presented for participant demographics, medical and outcome variables. Sex will be used in subgroup analysis of primary and secondary outcomes. It will also be a covariate for exploratory analysis in corresponding models. All analyses will adhere to the intention-to-treat principle.
- Qualitative data: Qualitative data will be analyzed inductively following a theoretical thematic approach. Data will be coded, with codes combined into larger categories and theme, with the goal of highlighting participant experiences and acceptability (barriers, facilitators) of the OPAL platform and intervention. Data collection and analysis will occur concurrently in order to enable refinement of interview/focus guide questions and deeper exploration of emerging themes.
Primary outcome: The primary outcome (sit to stand test; time to do 5 sit-to-stands) will be analyzed by linear mixed models with random effects, adjusted for baseline score as a covariate. Sites will be entered as random effects.
Secondary/exploratory outcomes: (1) Quantitative outcomes: Similar types of models will be used for continuous secondary/exploratory outcomes. To examine predictors of exercise and nutrition adherence (e.g. COM-B results), generalized linear models with binary outcome will be employed. To evaluate the potential effect of selected demographic variables on outcomes, as an exploratory analysis, models will be adjusted for clinically significant variables (e.g. sex, gender, digital technology proficiency). Results will be primarily descriptive. Exploratory per-protocol analysis will be performed, and the results will be presented if substantial differences are found between this group and the intention-to-treat group.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Foothills Medical Centre
-
Edmonton, Alberta, Canada, T6G1Z1
- Kaye Edmonton Clinic
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Gordon and Leslie Diamond Health Care Centre
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- London Health Sciences Centre
-
Toronto, Ontario, Canada, M5G 0A3
- Toronto General Hospital - Ajmera Transplant Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H4A3J1
- McGill University Health Centre
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
≥18 years old with cirrhosis (confirmed with transient elastography by FibroScan, histology, or imaging-based assessment with compatible clinical picture), referred for transplant and are assessed to have a high likelihood of being listed according to a preliminary review by hepatologist or are already listed for LT, are pre-frail or frail on the liver frailty index (LFI) or (added August 30, 2024) pre-frail or frail on the TeLeFI (prefrail LFI 3.2-4.3 and frail LFI ≥4.4), have English or French language proficiency, and own an internet-connected device.
Exclusion Criteria:
- Listed for living related donor transplantation with expected time on the wait list <12 weeks, or model for end-stage liver disease (MELD-Na) Score >26 (Justification: time to transplant is very short)
- Robust status on frailty testing (LFI 0-3.1) (Justification: unlikely to see benefit)
- Unable to provide informed consent
- Presence of a clinical condition that makes the intervention unsafe or infeasible (e.g. unable to follow instruction) or unsafe environment for virtual participation
- Life expectancy less than 6 months, compassionate care (clinician judgment) (Justification: unlikely to see benefit)
- Recent variceal bleed or history of varices not on adequate prophylaxis (Justification: acute exercise increases portal pressure
- Transplant indication is cholangiocarcinoma.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Prehabilitation Group
The prehabilitation group will be provided with access to the online digital web platform which contains the weekly acceptance and commitment therapy based education videos, nutrition intervention, and exercise intervention. |
12-weeks of online prehabilitation programming including: 1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk. 2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos). 3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence. |
|
Nessun intervento: Usual Care
This group will receive standard care for LT candidates with cirrhosis and will be provided with standard online exercise, nutrition, and behavioural resources. Control participants will not receive access to the online digital platform. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in time to do 5-sit-to-stands from baseline
Lasso di tempo: Week 0
|
A time to complete 5 chair stands of >15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform |
Week 0
|
|
Change in time to do 5-sit-to-stands from baseline
Lasso di tempo: Week 12
|
A time to complete 5 chair stands of >15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform |
Week 12
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in liver frailty index from baseline
Lasso di tempo: Week 0
|
Liver frailty will be assessed with a cirrhosis-specific tool. The in-person LFI which includes grip strength, chair stand and balance testing, or the virtual TeLeFI which includes virtual FTSST, three stance balance test, and selected questions from validated surveys. The LFI is an independent predictor of waitlist mortality and hospitalization. The LFI score can be calculated using an online calculator (available at http://liverfrailtyindex.ucsf.edu), with patient physical frailty categorized as robust, prefrail, and frail according to their index (index < 3.2, robust; 3.2-4.5, prefrail; and >4.5, frail). Higher scores mean a worse outcome. |
Week 0
|
|
Change in liver frailty index from baseline
Lasso di tempo: Week 12
|
Liver frailty will be assessed with a cirrhosis-specific tool. The in-person LFI which includes grip strength, chair stand and balance testing, or the virtual TeLeFI which includes virtual FTSST, three stance balance test, and selected questions from validated surveys. The LFI is an independent predictor of waitlist mortality and hospitalization. The LFI score can be calculated using an online calculator (available at http://liverfrailtyindex.ucsf.edu), with patient physical frailty categorized as robust, prefrail, and frail according to their index (index < 3.2, robust; 3.2-4.5, prefrail; and >4.5, frail). Higher scores mean a worse outcome. |
Week 12
|
|
Changes in virtual physical function testing over time (2-min step test)
Lasso di tempo: Week 0
|
The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes. The literature supports good correlation of this virtual measure when compared to in-person testing |
Week 0
|
|
Changes in virtual physical function testing over time (2-min step test)
Lasso di tempo: Week 12
|
The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes. The literature supports good correlation of this virtual measure when compared to in-person testing |
Week 12
|
|
Change in health-related quality of life from baseline (CLDQ)
Lasso di tempo: Week 0
|
The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis. Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL. |
Week 0
|
|
Change in health-related quality of life from baseline (CLDQ)
Lasso di tempo: Week 12
|
The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis. Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL. |
Week 12
|
|
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
Lasso di tempo: Week 0
|
The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement. |
Week 0
|
|
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
Lasso di tempo: Week 12
|
The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement. |
Week 12
|
|
Qualitative Acceptability Data
Lasso di tempo: Week 12
|
Inductive analysis of post-trial semi-structured interviews/focus groups with participants |
Week 12
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in time to do 5-sit-to-stands from baseline
Lasso di tempo: Week 8
|
A time to complete 5 chair stands of >15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform Completed at week 8 to account for the possibility of transplantation or loss-to-follow-up before the end of the 12 weeks. |
Week 8
|
|
Change in sarcopenia from baseline
Lasso di tempo: Week 0
|
Calf circumference is a simple measure for appendicular skeletal muscle and predicting sarcopenia |
Week 0
|
|
Change in sarcopenia from baseline
Lasso di tempo: Week 12
|
Calf circumference is a simple measure for appendicular skeletal muscle and predicting sarcopenia |
Week 12
|
|
Change in distance in the 6 minute walk test from baseline
Lasso di tempo: Week 0
|
6MWT distance correlates with waitlist mortality and QoL and is recommended by the American Society of Transplantation. It is associated with protein intake, activity level and physical function/ frailty. |
Week 0
|
|
Change in distance in the 6 minute walk test from baseline
Lasso di tempo: Week 12
|
6MWT distance correlates with waitlist mortality and QoL and is recommended by the American Society of Transplantation. It is associated with protein intake, activity level and physical function/ frailty. |
Week 12
|
|
Change in covert hepatic encephalopathy from baseline
Lasso di tempo: Week 0
|
The EncephalApp Stroop (Stroop) test is a reliable, easy-to-use diagnostic test for CHE. It evaluates psychomotor speed and cognitive flexibility. |
Week 0
|
|
Change in covert hepatic encephalopathy from baseline
Lasso di tempo: Week 12
|
The EncephalApp Stroop (Stroop) test is a reliable, easy-to-use diagnostic test for CHE. It evaluates psychomotor speed and cognitive flexibility. |
Week 12
|
|
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
Lasso di tempo: Week 8
|
The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement. |
Week 8
|
|
Change in health-related quality of life from baseline (CLDQ)
Lasso di tempo: Week 8
|
The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis. Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL. |
Week 8
|
|
Change in 6-item COM-B scale over time during intervention
Lasso di tempo: Week 4
|
Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 [strongly disagree] to 7 [strongly agree]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation |
Week 4
|
|
Change in 6-item COM-B scale over time during intervention
Lasso di tempo: Week 8
|
Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 [strongly disagree] to 7 [strongly agree]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation |
Week 8
|
|
Change in 6-item COM-B scale over time during intervention
Lasso di tempo: Week 12
|
Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 [strongly disagree] to 7 [strongly agree]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation. |
Week 12
|
|
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
Lasso di tempo: Post-transplant (12 weeks after transplant date)
|
The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement. |
Post-transplant (12 weeks after transplant date)
|
|
Change in health-related quality of life from baseline (CLDQ)
Lasso di tempo: Post-transplant (12 weeks after transplant date)
|
The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis. Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL. |
Post-transplant (12 weeks after transplant date)
|
|
Changes in virtual physical function testing over time (Single leg balance test)
Lasso di tempo: Week 0
|
The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance The literature supports good correlation of this virtual measure when compared to in-person testing |
Week 0
|
|
Changes in virtual physical function testing over time (Single leg balance test)
Lasso di tempo: Week 8
|
The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance The literature supports good correlation of this virtual measure when compared to in-person testing |
Week 8
|
|
Changes in virtual physical function testing over time (Single leg balance test)
Lasso di tempo: Week 12
|
The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance The literature supports good correlation of this virtual measure when compared to in-person testing |
Week 12
|
|
Changes in virtual physical function testing over time (Single leg balance test)
Lasso di tempo: Post-transplant (12 weeks after transplant date)
|
The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance The literature supports good correlation of this virtual measure when compared to in-person testing |
Post-transplant (12 weeks after transplant date)
|
|
Changes in virtual physical function testing over time (2-min step test)
Lasso di tempo: Week 8
|
The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes. The literature supports good correlation of this virtual measure when compared to in-person testing |
Week 8
|
|
Changes in virtual physical function testing over time (2-min step test)
Lasso di tempo: Post-transplant (12 weeks after transplant date)
|
The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes. The literature supports good correlation of this virtual measure when compared to in-person testing |
Post-transplant (12 weeks after transplant date)
|
|
Number of participants who died during the 12 week trial
Lasso di tempo: Week 12
|
Death will be collected through chart review |
Week 12
|
|
Number of hospitalizations and ambulatory clinic visits during the 12 week trial
Lasso di tempo: Week 12
|
Hospitalizations and ambulatory clinic visits will be collected through chart review |
Week 12
|
|
Number of participants who were transplanted during the 12 week trial
Lasso di tempo: Week 12
|
Data on transplantations occurring during the trial will be collected through chart review |
Week 12
|
|
Number of participants who died during the 2 years post-study completion
Lasso di tempo: 2 years post-study completion
|
Death will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research. |
2 years post-study completion
|
|
Number of hospitalizations and ambulatory clinic visits during the 2 years post-study completion
Lasso di tempo: 2 years post-study completion
|
Hospitalizations and ambulatory clinic visits will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research. |
2 years post-study completion
|
|
Number of participants who were transplanted during the 2 years post-study completion
Lasso di tempo: 2 years post-study completion
|
Data on transplantations occurring during the trial will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research. |
2 years post-study completion
|
|
Economic Evaluation
Lasso di tempo: Week 12
|
Healthcare access and hospital usage will be collected through patient survey. |
Week 12
|
|
Total Length of stay at time of transplant
Lasso di tempo: Post-transplant up to 3 months of the trial data collection period
|
In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain total length of stay at time of transplant |
Post-transplant up to 3 months of the trial data collection period
|
|
Intensive care unit length of stay at time of post transplant
Lasso di tempo: Post-transplant up to 3 months of the trial data collection period
|
In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain intensive care unit length of stay |
Post-transplant up to 3 months of the trial data collection period
|
|
Days of mechanical ventilation at time of post transplant
Lasso di tempo: Post-transplant up to 3 months of the trial data collection period
|
In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain days of mechanical ventilation |
Post-transplant up to 3 months of the trial data collection period
|
|
Discharge location from hospital at time of transplant
Lasso di tempo: Post-transplant up to 3 months of the trial data collection period
|
In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain discharge home from hospital (versus rehabilitation, nursing home or other institutional location) |
Post-transplant up to 3 months of the trial data collection period
|
|
Readmissions within 30 days at time of transplant
Lasso di tempo: Post-transplant up to 3 months of the trial data collection period
|
In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain any readmissions within 30 days. |
Post-transplant up to 3 months of the trial data collection period
|
|
Malnutrition
Lasso di tempo: Week 0
|
The Patient-Generated Subjective Global Assessment (PG-SGA) is an instrument for assessment of nutrition status in patients with cancer and other diseases. It contains both a patient and a practitioner section. A higher score means worse outcomes. The numerical PG-SGA score provides professionals with clearer guidelines as to the level of medical nutrition therapy needed in a given case, while the A, B, or C rating provides an overall picture of a patient's current status. (A = well nourished, B = moderately malnourished or suspected malnutrition and C = severely malnourished). |
Week 0
|
|
Malnutrition
Lasso di tempo: Week 12
|
The Patient-Generated Subjective Global Assessment (PG-SGA) is an instrument for assessment of nutrition status in patients with cancer and other diseases. It contains both a patient and a practitioner section. A higher score means worse outcomes. The numerical PG-SGA score provides professionals with clearer guidelines as to the level of medical nutrition therapy needed in a given case, while the A, B, or C rating provides an overall picture of a patient's current status. (A = well nourished, B = moderately malnourished or suspected malnutrition and C = severely malnourished). |
Week 12
|
|
Adverse events
Lasso di tempo: Week 12
|
Major: death or hospitalization for an event occurring during or up to 3 h after exercise; cardiovascular events (stroke, myocardial infarction); permanent disability; angina, syncope, arrhythmia; variceal bleeding. Minor: hypoglycemia, hyper- or hypotension requiring medical attention, musculoskeletal injury or fall. |
Week 12
|
|
Changes in health care provider support from baseline
Lasso di tempo: Week 0
|
Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up. |
Week 0
|
|
Changes in physical activity levels from baseline
Lasso di tempo: Week 0
|
Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to. |
Week 0
|
|
Changes in health care provider support from baseline
Lasso di tempo: Week 4
|
Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up. |
Week 4
|
|
Changes in physical activity levels from baseline
Lasso di tempo: Week 4
|
Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to. |
Week 4
|
|
Changes in health care provider support from baseline
Lasso di tempo: Week 8
|
Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up. |
Week 8
|
|
Changes in physical activity levels from baseline
Lasso di tempo: Week 8
|
Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to. |
Week 8
|
|
Changes in health care provider support from baseline
Lasso di tempo: Week 12
|
Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up. |
Week 12
|
|
Changes in physical activity levels from baseline
Lasso di tempo: Week 12
|
Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to. |
Week 12
|
|
Changes in functional status from baseline
Lasso di tempo: Week 0
|
The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI |
Week 0
|
|
Changes in functional status from baseline
Lasso di tempo: Week 8
|
The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI |
Week 8
|
|
Changes in functional status from baseline
Lasso di tempo: Week 12
|
The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI |
Week 12
|
|
Adherence to prehabilitation program goals
Lasso di tempo: Week 12
|
(i) 70% adherence to target protein intake and protein powder supplementation (assessed by dietary intake, nutrition check ins, platform metrics and monthly nutrition questionnaires), (ii) 70% adherence to exercise sessions (assessed by attendance, check ins, platform metrics) excluding study weeks with interruptions to programming due to health related issues (e.g. transplant dry runs, hospital admissions as these are common in patients awaiting LT) |
Week 12
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Puneeta Tandon, University of Alberta
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Manifestazioni neurologiche
- Malattie del sistema nervoso
- Manifestazioni neuromuscolari
- Processi patologici
- Disturbi della nutrizione
- Condizioni patologiche, anatomiche
- Malattie dell'apparato digerente
- Atrofia muscolare
- Atrofia
- Fibrosi
- Condizioni patologiche, segni e sintomi
- Comportamento
- Malattie nutrizionali e metaboliche
- Segni e sintomi
- Fragilità
- Malnutrizione
- Malattie del fegato
- Cirrosi epatica
- Sarcopenia
- Attività motoria
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- Pro00125367
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .